MassHealth Onpattro (patisiran) Monitoring Program

Onpattro (patisiran) requires prior authorization (PA) and will be managed by the Onpattro Monitoring Program.

Agent	Food and Drug Administration (FDA)-approved Indications and Limitations of Use
Onpattro (patisiran)	• Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Onpattro (patisiran)

Onpattro (patisiran) is a small interfering RNA therapy used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Onpattro Monitoring Program

Onpattro will require PA. MassHealth Drug Utilization Review (DUR) will be reaching out to prescribers quarterly to monitor for ongoing clinical effectiveness and to confirm sustained response.

Following PA approval, MassHealth DUR will outreach to the prescriber to inform of the Onpattro Monitoring Program. On a quarterly basis, the prescriber will need to submit documentation of the member's response to therapy. Information collected will include polyneuropathy disability (PND) score, liver transplant status, and documentation that the member has not discontinued therapy for any reason.

MassHealth DUR will be reviewing pharmacy and medical claims to determine the number of times Onpattro was administered each year. DUR will be reaching out at quarterly intervals. At these intervals, prescribers will inform DUR of the patient's response.

1. Onpattro [package insert]. San Diego (CA): Alnylam Pharmaceuticals, Inc. 2020 Feb.